Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 12, 2012, Pages 3397-3405

  Espana P P ^a   Capelastegui, A ^a   Bilbao, A ^b   Diez, R ^a   Izquierdo, F ^a   Lopez De Goicoetxea, M J ^a   Gamazo, J ^a   Medel, F ^c   Salgado, J ^c   Gorostiaga, I ^c   Quintana, J M ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c General Practice Comarca Interior   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; LEVOFLOXACIN; MACROLIDE; PROCALCITONIN;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CURB 65 SEVERITY SCORE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIAL IDENTIFICATION; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SCORING SYSTEM; SPAIN; TREATMENT PLANNING; VIRUS PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CLINICAL MEDICINE; COMMUNITY-ACQUIRED INFECTIONS; DECISION SUPPORT TECHNIQUES; FEMALE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; ROC CURVE; SPAIN;

EID: 84872172099     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-012-1708-5     Document Type: Article

References (46)

1. Lim WS, Woodhead M; British Thoracic Society (2011) British Thoracic Society adult community acquired pneumonia audit 2009/10. Thorax 66(6):548-549
2. Welte T, Torres A, Nathwani D (2010) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67(1):71-79
3. Marrie TJ (1994) Community-acquired pneumonia. Clin Infect Dis 18:501-515 (Pubitemid 24106900)
4. Gleason PP, Kapoor WN, Stone RA et al (1997) Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 278:32-39 (Pubitemid 27274513)
5. Lim WS, van der Eerden MM, Laing R et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377-382 (Pubitemid 36560938)
6. Carratalà J, Fernández-Sabé N, Ortega L et al (2005) Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann Intern Med 142:165-172 (Pubitemid 40189108)
7. España PP, Capelastegui A, Quintana JM et al (2003) A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 21(4):695-701 (Pubitemid 36432527)
8. Atlas SJ, Benzer TI, Borowsky LH et al (1998) Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 158:1350-1356 (Pubitemid 28287529)
9. Marrie TJ, Lau CY, Wheeler SL et al (2000) A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 283:749-755 (Pubitemid 30084614)
10. Chalmers JD, Akram AR, Hill AT (2011) Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 37(4):858-864
11. Labarere J, Stone RA, Obrosky DS et al (2007) Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis. Chest 131(2):480-488 (Pubitemid 46280409)
12. Brown JS (2009) Biomarkers and community-acquired pneumonia. Thorax 64:556-558
13. Christ-Crain M, Opal SM (2010) Clinical review: the role of biomarkers in the diagnosis and management of communityacquired pneumonia. Crit Care 14:203
14. Halm EA, Teirstein AS (2002) Clinical practice. Management of community-acquired pneumonia. N Engl J Med 347:2039-2045 (Pubitemid 35461661)
15. Menéndez R, Torres A, Aspa J et al (2010) Neumonía adquirida en la comunidad. Nueva normativa de la Sociedad de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol 46(10):543-558
16. Lim WS, Baudouin SV, George RC; Pneumonia Guidelines Committee of the BTS Standards of Care Committee et al (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64(Suppl 3):iii1-iii55
17. Mandell LA, Wunderink RG, Anzueto A; Infectious Diseases Society of America; American Thoracic Society et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27- S72 (Pubitemid 46290553)
18. Chalmers JD, Singanayagam A, Akram AR et al (2011) Safety and efficacy of CURB65-guided antibiotic therapy in communityacquired pneumonia. J Antimicrob Chemother 66(2):416-423
19. Flanders SA, Stein J, Shochat G et al (2004) Performance of a bedside C-reactive protein test in the diagnosis of communityacquired pneumonia in adults with acute cough. Am J Med 116 (8):529-535 (Pubitemid 38452644)
20. Simon L, Gauvin F, Amre DK et al (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39(2):206- 217 (Pubitemid 38971491)
21. Gilbert DN (2010) Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 48:2325-2329
22. Gilbert DN (2011) Procalcitonin as a biomarker in respiratory tract infection. Clinic Infect Dis 52(Suppl 4):S346-S350
23. Masiá M, Gutiérrez F, Shum C et al (2005) Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 128(4):2223-2229 (Pubitemid 41507563)
24. Prat C, Domínguez J, Andreo F et al (2006) Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 52(3):169-177 (Pubitemid 43286182)
25. Schuetz P, Batschwaroff M, Dusemund F et al (2010) Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis 29(3):269- 277
26. Capelastegui A, España PP, Bilbao A; Poblational Study of Pneumonia (PSoP) Group et al (2010) Study of communityacquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect 61(5):364-371
27. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36 (Pubitemid 12142173)
28. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843 (Pubitemid 13033817)
29. Ewig S, Ruiz M, Mensa J et al (1998) Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 158:1102-1108 (Pubitemid 28489008)
30. Fine MJ, Auble TE, Yealy DM et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243-250 (Pubitemid 27044625)
31. España PP, Capelastegui A, Gorordo I et al (2006) Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 174:1249-1256 (Pubitemid 44924826)
32. Aliberti S, Ramirez J, Cosentini R et al (2011) Low CURB-65 is of limited value in deciding discharge of patients with communityacquired pneumonia. Respir Med 105(11):1732-1738
33. Ronan D, Nathwani D, Davey P et al (2010) Predicting mortality in patients with community-acquired pneumonia and low CURB- 65 scores. Eur J Clin Microbiol Infect Dis 29(9):1117-1124
34. Blasi F, Stolz D, Piffer F (2010) Biomarkers in lower respiratory tract infections. Pulm Pharmacol Ther 23(6):501-507
35. Menéndez R, Martínez R, Reyes S et al (2009) Biomarkers improve mortality prediction by prognostic scales in communityacquired pneumonia. Thorax 64(7):587-591
36. Krüger S, Ewig S, Giersdorf S et al (2010) Cardiovascular and inflammatory biomarkers to predict short and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 182:1426-1434
37. Huang DT, Weissfeld LA, Kellum JA et al (2008) Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 52(1):48-58
38. Krüger S, Ewig S, Marre R et al (2008) Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 31(2):349-355
39. Huang DT, Angus DC, Kellum JA et al (2009) Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 136(3):823-831
40. Claessens YE, Mathevon T, Kierzek G et al (2010) Accuracy of Creactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med 36(5):799-809
41. Krüger S, Ewig S, Papassotiriou J et al (2009) Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 10:65
42. Hedlund J, Strålin K, Ortqvist A et al (2005) Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. Scand J Infect Dis 37(11-12):791-805
43. Niederman MS (2010) Viral community-acquired pneumonia: if we do not diagnose it and do not treat it, can it still hurt us? Chest 138(4):767-769
44. Christ-Crain M, Stolz D, Bingisser R et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174(1):84-93 (Pubitemid 43955248)
45. Burkhardt O, Ewig S, Haagen U et al (2010) Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 36(3):601-607
46. Long W, Deng X, Zhang Yet al (2011) Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with communityacquired pneumonia. Respirology 16(5):819-824